Furthermore, other immunotherapies such as dual–ICIs, cancer vaccine, ACT and T–cell immunoreceptor with Ig and ITIM domain (TIGIT) blockade also showed clinical value in selected lung cancer patients (21–24). This evidence concerns the gene TIGIT and lung carcinoma.